Ictio Biotechnologies

What Ictio Biotechnologies does

Ictio Biotechnologies (legal name Consorcio Tecnológico de Sanidad Acuícola S.A.) is a privately held Chilean public-private consortium founded in 2014 in Providencia, Santiago, to develop biotechnology solutions for the Chilean salmon farming industry. The company originated from scientific research conducted at the Universidad de Santiago de Chile's Centro de Biotecnología Acuícola (CBA) and was established together with founding partners Salmones Blumar S.A., Productos del Mar Ventisqueros S.A., and biotechnology firm ActivaQ S.A. It operates under Chile's Ley N°21.516/21.640/21.722 public-private consortium framework.

The company's product portfolio spans three integrated pillars for aquaculture health management: prevention (vaccine prototypes targeting Salmonid Rickettsial Septicemia and Flavobacterium), diagnosis (simultaneous diagnostic kits and physiological stress marker determination tools for early immune status assessment), and treatment (passive immunization solutions, immuno-stimulant probiotics, antiparasitic treatments, and broad-spectrum antimicrobial treatments). These products are built on proprietary wet-lab biotechnology originating from USACH-CBA and are targeted exclusively at Chilean salmon producers.

Ictio generates revenue via direct B2B sales of biotechnology products and through R&D services funded through the consortium structure and government programs such as Corfo's "Mueve tu innovación a la industria." Its customer base is concentrated in the Chilean salmoniculture vertical, with founding salmon producers serving as anchor customers and co-developers. As of 2024 the company has expanded its ecosystem positioning through participation in the Nuevo Consorcio Aqua Biotechnology translational aquaculture center. The company is small (11-50 employees), has no disclosed revenue, no disclosed funding rounds, and operates only in Chile.

Name

Ictio Biotechnologies

Legal name

Consorcio Tecnológico de Sanidad Acuícola S.A.

Website

https://ictiobiotech.cl

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Ictio Biotechnologies is a Chilean public-private consortium developing vaccines, diagnostic kits, and therapeutic treatments for disease management in the Chilean salmon farming industry.

Ownership category

akta.pro rank

Product category

Aquaculture Health Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Other Aquaculture (112519)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYAFAEAAAK

Aquaculture Health, Biosecurity & Veterinary Services

Agriculture & Food Production/Animal Production & Aquaculture/Aquaculture (Fish & Shellfish Farming)

SECONDARYHLAMAKAE

Aquaculture/Fish & Shrimp Vaccines

Healthcare & Life Sciences/Veterinary & Animal Health/Animal Vaccines

SECONDARYAFAEANAE

Aquaculture & Fish Health Services

Agriculture & Food Production/Animal Production & Aquaculture/Animal Health & Veterinary Services

SECONDARYHLAMAHAF

Aquaculture Feed & Nutrition

Healthcare & Life Sciences/Veterinary & Animal Health/Animal Nutrition & Therapeutic Diets

Keywords

• Aquaculture health biotechnology
• Salmon vaccines
• Fish disease diagnostics
• Aquatic veterinary therapeutics
• Salmon aquaculture treatments

Headquarters

HQ city

Santiago

HQ country

Chile

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Biotechnology Products and Services: Development and commercialization of vaccines, diagnostic kits, and treatment solutions for the Chilean salmon aquaculture industry. Products include vaccine prototypes, diagnostic tools, and therapeutic treatments targeting SRS and Flavobacterium diseases.
2. Research and Development Services: Public-private consortium providing R&D services and technology development for aquaculture health management, funded through government programs like Corfo and strategic partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ictio Biotechnologies develops and commercializes a biotechnology portfolio for aquaculture health management in the Chilean salmon industry. Its offerings span prevention (vaccine prototypes against SRS and Flavobacterium), diagnosis (simultaneous diagnostic kits and physiological stress marker tools), and treatment (passive immunization solutions, immuno-stimulant probiotics, antiparasitic treatments, and broad-spectrum antimicrobials). The company operates as a public-private consortium bridging academic research from Universidad de Santiago de Chile with salmon producers and a biotechnology firm.

Product overview

Ictio Biotechnologies (Consorcio Tecnológico de Sanidad Acuícola S.A.) is a biotechnology consortium offering a portfolio of aquatic health solutions for the Chilean salmon industry. The product portfolio spans three core areas: Prevention (vaccine prototypes against SRS and Flavobacterium), Diagnosis (simultaneous diagnostic kits and physiological stress marker determination tools for early immune status assessment), and Treatment (passive immunization solutions, immuno-stimulant probiotics, antiparasitic treatments, and broad-spectrum antimicrobial treatments). These products work together as an integrated approach to improving salmon farm productivity through disease prevention, early diagnosis, and effective treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• Vaccine Prototypes against SRS and Flavobacterium Prototype vaccines targeting Salmonid Rickettsial Septicemia (SRS) and Flavobacterium infections in salmon, intended for commercial release to Chilean salmon farming companies in the short term.
• Simultaneous Diagnostic Kits Biotechnological tools enabling simultaneous diagnosis of diseases in fish populations, allowing early detection of health status in salmon.
• Physiological Stress Marker Determination Tools Tools for determining physiological stress markers used to anticipate the immunological state of fish populations under study.
• Passive Immunization Solutions Formulated solutions for disease treatment in salmon based on passive immunization techniques.
• Immuno-stimulant Probiotics Probiotic formulations designed to stimulate the immune response in salmonid populations.
• Antiparasitic Treatments Treatment solutions targeting parasitic infections in aquaculture species.
• Broad-Spectrum Antimicrobial Treatments Antimicrobial treatments of broad spectrum designed for wide-ranging disease control in aquaculture.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core, supporting and minor.

• Universidad de Santiago de Chile - Centro de Biotecnología Acuícola (CBA)coreStrategic or Co-development Partner · 1 January 2014Founding academic partner providing scientific research foundation. ICTIO was founded based on scientific work from the Centro de Biotecnología Acuícola (CBA) of Universidad de Santiago de Chile. This partnership provides the research backbone for the consortium's biotechnology development.
• Salmones Blumar S.A.coreStrategic or Co-development Partner · 1 January 2014Founding private partner and salmon producer company. One of the two founding salmon farming companies in the public-private alliance, providing industry expertise and commercial application context for ICTIO's biotechnology solutions.
• Productos del Mar Ventisqueros S.A.coreStrategic or Co-development Partner · 1 January 2014Founding private partner and salmon producer company. One of the two founding salmon farming companies in the public-private alliance, contributing industry knowledge and real-world aquaculture health challenges for product development.
• ActivaQ S.A.coreStrategic or Co-development Partner · 1 January 2014Founding biotechnology company partner in the consortium. Brings biotechnology expertise and development capabilities to complement the academic research and industry application sides of the partnership.
• Corporación de Fomento de la Producción (Corfo)supportingOthersGovernment development agency facilitating innovation-to-industry programs. ICTIO participated in Corfo's "Mueve tu innovación a la industria" program alongside INAPI, which represents an important step in commercialization of ICTIO's products.
• Instituto Nacional de Propiedad Industrial (INAPI)supportingOthersNational industrial property institute partnered with Corfo to run the "Mueve tu innovación a la industria" program, supporting ICTIO's path to market for its biotechnology products.
• Nuevo Consorcio Aqua BiotechnologyminorStrategic or Co-development PartnerNew Translational Aquaculture Center consortium announced in June 2024. ICTIO participates as a member in this center that promotes innovation in the aquaculture sector.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Others

• BioMar: Global aquaculture feed producer. While not a vaccine/diagnostic competitor, BioMar's functional feeds and health-focused nutrition intersect with ICTIO's probiotics and feed-additive-adjacent offerings.
• Salmones Blumar: One of ICTIO's founding consortium partners and a major Chilean salmon producer. It is not a competitor but a key stakeholder and likely anchor customer; relevant as a Chilean salmon industry reference comparable.
• Productos del Mar Ventisqueros: Chilean salmon producer and ICTIO's other founding private partner. Like Blumar, it is a key stakeholder and prospective anchor customer rather than a direct competitor.

Broad incumbents

• Virbac: Global animal health company with a presence in aquaculture pharmaceuticals and biologicals. Its broad portfolio overlaps with ICTIO's vaccine and antimicrobial offerings in salmon.
• MSD Animal Health (Intervet): Global animal health division of Merck offering vaccines, anti-infectives, and diagnostics for aquaculture, including salmon. It is a broad incumbent competing across ICTIO's prevention, diagnosis, and treatment categories.
• Elanco Animal Health: Global animal health company with an aquaculture portfolio including vaccines and therapeutics for farmed fish. As a broad incumbent, it overlaps with ICTIO's integrated prevention/treatment platform for salmon.

Emerging players

• AquaBounty Technologies: Aquaculture biotechnology company focused on productivity-enhancing biotech for farmed fish. Although focused on genetics rather than health, it shares ICTIO's biotech-for-aquaculture positioning.

Direct peers

• Pharmaq (Zoetis): Part of Zoetis, Pharmaq is one of the world's leading aquaculture health companies, developing and commercializing vaccines and therapeutics for salmon and other farmed fish — directly competing with ICTIO's vaccine and treatment portfolio for Chilean salmon.
• Centrovet: Chilean veterinary pharmaceutical company specializing in animal health products for aquaculture and livestock, including vaccines for salmon — a direct regional competitor in Chilean salmon health.
• Benchmark Holdings: UK-listed aquaculture health company offering vaccines, diagnostics, and specialty nutrition for salmon and other farmed fish — closely matching ICTIO's integrated aquaculture health model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ictio-biotechnologies

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ictio Biotechnologies